The novel β2-selective proteasome inhibitor LU-102 synergizes with bortezomib and carfilzomib to overcome proteasome inhibitor resistance of myeloma cells

Proteasome inhibitor resistance is a challenge for myeloma therapy. Bortezomib targets the β5 and β1 activity, but not the β2 activity of the proteasome. Bortezomib-resistant myeloma cells down-regulate the activation status of the unfolded protein response, and up-regulate β2 proteasome activity. T...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Marianne Kraus, Juergen Bader, Paul P. Geurink, Emily S. Weyburne, Anne C. Mirabella, Tobias Silzle, Tamer B. Shabaneh, Wouter A. van der Linden, Gerjan de Bruin, Sarah R. Haile, Eva van Rooden, Christina Appenzeller, Nan Li, Alexei F. Kisselev, Herman Overkleeft, Christoph Driessen
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Ferrata Storti Foundation 2015-10-01
coleção:	Haematologica
Acesso em linha:	https://haematologica.org/article/view/7530
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!